DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ZEMURON
Clinical Trials for Zemuron
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00124722 | A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-12-01 | The primary purpose of this study is to evaluate the time course of muscle relaxation after administration of three different single intravenous bolus doses of rocuronium bromide for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) in term neonates (birth to <28 days old), infants (28 days to <=3 months) and toddlers (>3 months to <=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age). Subjects in each of the age groups will be randomized to one of 3 Zemuron® doses: 0.45 mg/kg, 0.6 mg/kg, or 1.0 mg/kg. |
| NCT00124735 | A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-10-01 | The primary purpose of this study is to determine the dose requirements of rocuronium bromide when administered as a bolus dose (a single, large dose) for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) and when administered by either continuous infusion or bolus doses for maintenance of muscle relaxation in term neonates (birth to <28 days old), infants (28 days to <=3 months) and toddlers (>3 months to <=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age). |
| NCT00474253 | Comparison of Recovery From Rocuronium 1.2 mg/kg Followed By Org 25969 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-02-01 | The purpose of the trial is to demonstrate a faster recovery from neuromuscular block induced by 1.2 mg/kg Zemuron® after reversal at 3 minutes by 16.0 mg/kg of Org 25969 compared with recovery after a neuromuscular block induced by 1.0 mg/kg succinylcholine. |
| NCT00475215 | Evaluation of Safety and Efficacy of Org 25969 in Subjects With or Having a Past History of Pulmonary Disease (19.4.308)(P05932) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-10-01 | The purpose of the trial is to research the safety and to show faster recovery after administration of 2.0 mg/kg or 4.0 mg/kg Org 25969 (sugammadex) given as a reversal agent for Zemuron® in subjects diagnosed with or having a history of pulmonary disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Zemuron
Condition Name
Condition MeSH
Clinical Trial Locations for Zemuron
Trials by Country
Clinical Trial Progress for Zemuron
Clinical Trial Phase
Clinical Trial Sponsors for Zemuron
Sponsor Name
